Exelixis, Inc. (EXEL)
Exelixis develops and sells cancer medicines, led by CABOMETYX, for physicians and their patients. It last closed at $68.50 on Nov 17, up 2.09% on the day. EXEL reports earnings on Tue, Feb 9, 2027. The average 12-month price target from 8 analysts is $63.25 (-7.7% from the last close), with a high of $78.00 and a low of $54.00. Analyst consensus is Hold, based on the latest ratings from 8 firms (3 buy, 5 hold, 0 sell). Over the past 90 days StreetAlpha recorded 2 whale options trades in EXEL, 50% of them bullish and 50% bearish. In the past 30 days there were 1 dark pool print totaling $823K, the largest $823K.
Key Stats
Last 12 monthsNot reported for this period.
From EXEL's SEC filings, latest 10-Q for the period ending Oct 2, 2026 (filed Oct 29). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 8 analysts who set a price target on EXEL in the past 90 days. The average target is $63.25, with a high of $78.00 and a low of $54.00, compared with the last close of $68.50.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 13 | Morgan Stanley | Target lowered | Hold | $60 → $57 |
| Nov 5 | Leerink Partners | Maintained | Hold | $58 |
| Nov 2 | HC Wainwright & Co. | Maintained | Buy | $78 |
| Oct 30 | TD Cowen | Maintained | Buy | $76 |
| Oct 30 | Morgan Stanley | Target raised | Hold | $53 → $60 |
Technical Analysis
The stock is 0% above its 20 day and 9% above its 50 day average. It is 23% above its 200 day average, so the longer trend is still up. Momentum is neutral (RSI 56). The nearest support is the 20 day average at $68.38, and the nearest resistance the Pivot R1 at $69.27.
| RSI (14) | 55.78 | Middle of its range | Neutral |
| MACD | 1.95 | Below its signal line | Bearish |
| Stochastic | 38.6 | Middle of its range | Neutral |
| ADX (14) | 36.5 | Trending up | |
| Williams %R | -60.1 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | -17.7 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −5.3% | Change over 10 sessions | Bearish |
| ATR (14) | $2.18 | Typical daily range, 3.2% of price |
| RSI (14) | 74.63 | Overbought above 70 | Overbought |
| MACD | 4.98 | Above its signal line | Bullish |
| Stochastic | 80.1 | Near the top of its range | Overbought |
| ADX (14) | 42.3 | Strong uptrend | |
| Williams %R | -22.7 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | 127.6 | Oversold below −100, overbought above 100 | Overbought |
| Rate of change | +22.1% | Change over 10 sessions | Bullish |
| ATR (14) | $4.07 | Typical daily range, 5.9% of price |
What happened before
See how EXEL did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How EXEL has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.
Whale Options Flow
90DNo whale options trades in EXEL in the last 90 days.
Dark Pool
30DEXEL Institutional Ownership
Full report →- ●360 buying vs 349 selling
- ▼Held by funds -5.5 pts
- ▲Funds holding +14
- ▼Superinvestors: 0 added, 4 cut
- ▼Put/call 0.89 to 1.57
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 774 | 760 | +1.8% |
| In funds' top 10 | 12 | 9 | +33.3% |
| Held by funds | 101.3% | 106.7% | −5.5 pts |
| New / increased | 95 / 265 | 123 / 257 | −5.3% |
| Reduced / sold out | 275 / 74 | 280 / 69 | 0.0% |
| Put/call ratio | 1.57 | 0.89 | +77.1% |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether EXEL is in one of them and how their past EXEL trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered EXEL in an article yet. Here's the latest on the wider market.
EXEL Congress Trades
All congress trades →| Person | Type | Amount | Traded | Filed | Delay |
|---|---|---|---|---|---|
| Ro KhannaD · CA | Sell | $1K – $15K | Jan 10, 2024 | Feb 5, 2024 | 26 d |
| Ro KhannaD · CA | Buy | $1K – $15K | Dec 6, 2022 | Jan 3, 2023 | 28 d |
| Donna ShalalaD · FL | Sell | $1K – $15K | Jun 4, 2019 | Apr 27, 2020 | 328 d |
| Donna ShalalaD · FL | Sell (partial) | $1K – $15K | Apr 16, 2019 | Apr 27, 2020 | 377 d |
| Donna ShalalaD · FL | Buy | $1K – $15K | Feb 6, 2019 | Apr 27, 2020 | 446 d |
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Exelixis
Exelixis is a biopharmaceutical company based in Alameda, California, that develops and sells medicines for cancer. Its main product is CABOMETYX, a cabozantinib tablet used to treat several forms of kidney, liver, thyroid and neuroendocrine cancer, and it also sells COMETRIQ for medullary thyroid cancer. Its medicines are prescribed by physicians and taken by patients, with partners such as Ipsen and Takeda handling sales in markets outside the U.S. Its pipeline includes zanzalintinib, which is under review for colorectal cancer.
- Headquarters
- Alameda, CA
- Founded
- 1994
- Website
- exelixis.com ↗





